scholarly journals Intralesional nerve-sparing surgery versus non-surgical treatment for giant cell tumor of the sacrum

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Shinji Tsukamoto ◽  
Nikolin Ali ◽  
Andreas F. Mavrogenis ◽  
Kanya Honoki ◽  
Yasuhito Tanaka ◽  
...  
Keyword(s):  
Surgical Treatment ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Cell Tumor ◽  
Nerve Sparing ◽  
Giant Cell Tumors ◽  
Adjuvant Therapies ◽  
The Mean ◽  
Non Surgical Treatment ◽  
Surgical Group

Abstract Background There is no standard treatment for giant cell tumors of the sacrum. We compared the outcomes and complications in patients with sacral giant cell tumors who underwent intralesional nerve-sparing surgery with or without (neo-) adjuvant therapies versus those who underwent non-surgical treatment (denosumab therapy and/or embolization). Methods We retrospectively investigated 15 cases of sacral giant cell tumors treated at two institutions between 2005 and 2020. Nine patients underwent intralesional nerve-sparing surgery with or without (neo-) adjuvant therapies, and six patients received non-surgical treatment. The mean follow-up period was 85 months for the surgical group (range, 25–154 months) and 59 months (range, 17–94 months) for the non-surgical group. Results The local recurrence rate was 44% in the surgical group, and the tumor progression rate was 0% in the non-surgical group. There were two surgery-related complications (infection and bladder laceration) and three denosumab-related complications (apical granuloma of the tooth, stress fracture of the sacroiliac joint, and osteonecrosis of the jaw). In the surgical group, the mean modified Biagini score (bowel, bladder, and motor function) was 0.9; in the non-surgical group, it was 0.5. None of the 11 female patients became pregnant or delivered a baby after developing a sacral giant cell tumor. Conclusions The cure rate of intralesional nerve-sparing surgery is over 50%. Non-surgical treatment has a similar risk of complications to intralesional nerve-sparing surgery and has better functional outcomes than intralesional nerve-sparing surgery, but patients must remain on therapy over time. Based on our results, the decision on the choice of treatment for sacral giant cell tumors could be discussed between the surgeon and the patient based on the tumor size and location.

Giant Cell Tumor of the Talar Neck

2007 ◽  
Vol 97 (3) ◽  
pp. 225-228 ◽  
Author(s):  
Hakan Selek ◽  
Hamza Özer ◽  
Sacit Turanli ◽  
Özlem Erdem
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Clinical Signs ◽  
Cell Tumor ◽  
Giant Cell Tumors ◽  
Radiographic Appearance ◽  
Aneurysmal Bone Cysts ◽  
Tumors Of Bone ◽  
Brown Tumors ◽  
Small Bones

We describe a patient with a giant cell tumor in the talar head and neck of the left foot who was diagnosed as having osteochondritis dissecans and treated with arthroscopic drilling in this same location 3 years earlier. Giant cell tumors can be confused with several conditions, including giant cell reparative granulomas, brown tumors, and aneurysmal bone cysts. Giant cell tumors of bone typically occur in the epiphysis of long bones, including the distal femur and proximal tibia. They are uncommonly found in the small bones of the foot or ankle, and talar involvement is rare. Despite this rarity, the radiographic appearance and clinical signs of talar lesions should be considered in the differential diagnosis of nontraumatic conditions in the foot. (J Am Podiatr Med Assoc 97(3): 225–228, 2007)

Intramuscular Tenosynovial Giant Cell Tumor Harboring a Novel CSF1-CD96 Fusion Transcript

2021 ◽  
pp. 106689692110498
Author(s):  
Haider Mejbel ◽  
Gene P. Siegal ◽  
Shi Wei
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Gene Rearrangement ◽  
Fusion Transcript ◽  
Cell Tumor ◽  
Molecular Profile ◽  
Small Subset ◽  
Fusion Partner ◽  
Giant Cell Tumors ◽  
Tenosynovial Giant Cell Tumor

Tenosynovial giant cell tumors typically arise in the synovium of joints, bursae, or tendon sheaths. They may occur in an intra- or extra-articular location and can be divided into localized and diffuse types. The neoplastic nature of the lesion has been supported by a recurrent CSF1 gene rearrangement in a small subset of lesional cells, of which the most common fusion partner is COL6A3. Herein, we report a case of intramuscular localized tenosynovial giant cell tumor harboring a novel CSF1-CD96 fusion transcript, thus expanding the molecular profile of this tumor.

scholarly journals Surgical treatment outcome of giant cell tumor of distal ulna: En bloc resection vs. curettage and bone graft

2018 ◽  
Vol 32 (1) ◽  
pp. 249-253
Author(s):  
Khodamorad Jamshidi ◽  
Mehrdad Bahrabadi ◽  
Abolfazl Bagherifard ◽  
Mehdi Mohamadpour
Keyword(s):  
Treatment Outcome ◽  
Surgical Treatment ◽  
Bone Graft ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
En Bloc Resection ◽  
Bloc Resection ◽  
Cell Tumor ◽  
Distal Ulna ◽  
En Bloc

scholarly journals Correlation between Campanacci’s radiological classification of giant cell tumor of bone and expression of Cyclin D1 and PCNA

2017 ◽  
Vol 7 (1) ◽  
pp. 47
Author(s):  
Eréndira G. Estrada-Villaseñor ◽  
Hidalgo Bravo Alberto ◽  
C. Bandala ◽  
P. De la Garza-Montano ◽  
Reyes Medina Naxieli ◽  
...  
Keyword(s):  
Cyclin D1 ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Descriptive Study ◽  
Cell Tumor ◽  
Giant Cell Tumors ◽  
Radiological Classification ◽  
Tumors Of Bone ◽  
Made In

Giant cell tumor of bone is considered by his behavior a benign but aggressive neoplasm. The objective of our study was to determine if there is a correlation between the Campanacci’s radiological classification of giant cell tumors of bone and the expression by immunohistochemistry of Cyclin D1 and proliferation cell nuclear antibody (PCNA). A retrospective and descriptive study was made. In total, there were 27 cases. All cases showed Cyclin D1 and PCNA positivity. Rho Spearman for Campanacci and Cyclin D1 expression was 0.06 and for Campanacci and PCNA was 0.418. We conclude that there is a positive correlation between PCNA expression in giant cell tumors of Bone and the Campanacci’s radiological classification II and III, butCyclin D1 expression was no related with radiologic features.

Giant Cell Tumor of the Ethmoid Sinus: An Unusual Cause of Proptosis in a Child

1982 ◽  
Vol 90 (4) ◽  
pp. 513-515 ◽  
Author(s):  
Steven D. Handler ◽  
Peter J. Savino ◽  
Robert G. Peyster ◽  
Norman J. Schatz
Keyword(s):  
Head And Neck ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Ethmoid Sinus ◽  
Cell Tumor ◽  
Giant Cell Tumors

Giant cell tumors (osteoclastoma) occur infrequently in the head and neck and are extremely rare in children. The occurrence of such a lesion in the ethmoid sinus of a 14-year-old girl is presented and discussed.

Recurrence Potential of Diffuse-Type Giant Cell Tumor in the Foot: Radiologic and Pathologic Features

2005 ◽  
Vol 26 (6) ◽  
pp. 474-478 ◽  
Author(s):  
Tominaga Shimizu ◽  
Takeshi Uehara ◽  
Tsutomu Akahane ◽  
Kenichi Isobe ◽  
Hideki Arai
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Tumor Resection ◽  
Cell Tumor ◽  
Cell Contact ◽  
Diffuse Type ◽  
Mri Findings ◽  
Giant Cell Tumors ◽  
Pathologic Features ◽  
Type Giant

Background: Aggressive musculoskeletal tumors in the foot, such as diffuse-type giant cell tumors or extra-abdominal desmoid tumors, are difficult to treat because the foot does not have enough soft tissue to allow wide tumor resection. We reviewed the clinical behavior of diffuse-type giant cell tumor in the foot and evaluated the recurrence potential of these tumors from radiologic and pathologic perspectives. Methods: Six patients with a mean age of 37.6 years were included in this study. Radiologic studies, including sonography, computed tomography (CT), magnetic resonance imaging (MRI), and bone and gallium citrate scintigraphy, were obtained followed by surgical treatment and histologic evaluation of the tumor. Results: Recurrence occurred in three patients. Although CT and MRI findings were similar in the recurrent and nonrecurrent tumors, marked differences were found between the two by scintigraphy; positive radiotracer uptake to the affected foot with gallium citrate scintigraphy was noted only in recurrent tumors, although positive accumulation was seen in all patients with bone scintigraphy. Histologically, the necrotic area and mitotic activity were more apparent in recurrent than in the nonrecurrent tumors, and tumor cell dyscohesion was noted in the former, (the intercellular space was increased). Conclusions: Repeated recurrence with tumor invasion into tarsal bone resulted in breakage of the tarsal arch that supports the body's weight. Amputation would be necessary for patients in whom the disease had progressed to obtain local cure and relief of pain. In the present study, we found two features of the recurrence potential of diffuse-type giant cell tumors: sparse cell to cell contact on pathologic examination and positive accumulation in the tumor on gallium citrate scintigraphy. We concluded that giant cell tumors with these two features have a strong potential for local recurrence, and thus require intensive followup.

Giant Cell Tumor of the Larynx

1998 ◽  
Vol 107 (8) ◽  
pp. 729-732 ◽  
Author(s):  
Kenneth O. Devaney ◽  
Alfio Ferlito ◽  
Alessandra Rinaldo
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Malignant Fibrous Histiocytoma ◽  
Fibrous Histiocytoma ◽  
Sarcomatoid Carcinoma ◽  
Cell Tumor ◽  
Long Bone ◽  
Giant Cell Tumors ◽  
Tentative Diagnosis ◽  
True Neoplasm

Among the more uncommon tumors that may sometimes be encountered in the laryngeal region is the recently described giant cell tumor of the larynx. This lesion is a true neoplasm, presumably of the fibrohistiocytic series. Histologically, it closely resembles the more familiar true giant cell tumor of long bone. The laryngeal giant cell tumors appear, to date, to be nonmetastasizing lesions; it is possible that they may recur locally if incompletely excised (although this remains to be demonstrated). In view of the rarity of these tumors, a tentative diagnosis of such a neoplasm should always prompt consideration of other (more frequently encountered) differential diagnostic possibilities, including cytologically malignant giant cell-rich tumors such as malignant fibrous histiocytoma and sarcomatoid carcinoma.

scholarly journals Results of the surgical treatment of diffuse pigmented villonodular synovitis (diffuse-type tenosynovial giant-cell tumor) of the knee

2021 ◽  
Vol 23 (5) ◽  
pp. 656-663
Author(s):  
S. I. Herasymenko ◽  
O. A. Kostogryz ◽  
Yu. O. Kostogryz ◽  
A. M. Babko ◽  
V. M. Mayko
Keyword(s):  
Surgical Treatment ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Treatment Algorithm ◽  
State Institution ◽  
Pigmented Villonodular Synovitis ◽  
Cell Tumor ◽  
Villonodular Synovitis ◽  
Tenosynovial Giant Cell Tumor ◽  
Pigmented Villonodular

The aim. To develop a treatment algorithm with the aim of improving the treatment results of diffuse pigmented villonodular synovitis of the knee. To study and analyze the results of surgical treatment of diffuse pigmented villonodular synovitis of the knee. Materials and methods. The study was based on the results of treatment of 48 patients with pathohistologically verified diagnosis of diffuse pigmented villonodular synovitis (tenosynovial giant cell tumor) of the knee undergoing treatment at the State Institution “Institute of Traumatology and Orthopedics of the National Academy of Medical Sciences of Ukraine” from 2010 to 2019. Results. The best functional results can be achieved in patients with diffuse pigmented villonodular synovitis of the knee in stage I of the disease. Using the method of mathematical statistics to evaluate the results obtained, we see that scores obtained through the Lysholm Scoring Scale were statistically significantly different in stages before a surgery (P = 0.000782), 3 months (P = 0.00005) and 6 months after the surgery (P = 0.04); but over time, these differences diminished and became actually insignificant 12 months after the surgery (P = 0.89). Conclusions. Applying our therapeutic algorithm for the treatment of patients with diffuse pigmented villonodular synovitis of the knee, the outcome of the Lysholm score was excellent in 22 % of patients, good – in 45 %, satisfactory – in 21 % and poor – in 12 % of patients.

Sign in / Sign up

Export Citation Format

Share Document